European pharmaceutical glass bottle packaging mar

  • Detail

The European pharmaceutical glass bottle packaging market is facing a test

it is estimated that the annual sales of pharmaceutical packaging materials in the whole Europe (including Eastern Europe) reached US $3.246 billion. The main packaging forms are containers and cardboard boxes, each accounting for 1/4 of the total sales volume. The second is blister eye packaging (including PVC strips and small bags), accounting for about 22% I. the rest is occupied by bottle seals, labels and other types of drug delivery systems. How to break the "import dependence" of the new material industry. In terms of materials, the sales of paper and paperboard account for 37%, the sales of plastics account for 28%, the sales of metal will continue to grow rapidly in the future, accounting for 26%, and the sales of glass only account for 9%

from now to 2007, the sales of packaging materials is expected to grow in parallel with the sales of drugs. The negative effects of reducing the packaging weight will be balanced by the high-value packaging trend. In fact, the sales of packaging may grow faster than the sales of drugs, although the range will not be too large. This is because pharmaceutical companies are willing to buy packaging that is more expensive, safer, vandal resistant, child resistant, convenient for the elderly and can protect privacy. Therefore, compared with the $3.2 billion in 1998, the sales of drug packaging reached $4billion in 2002 and will reach $5.1 billion in 2007. The growth rate of 5% ~ 6% in the first half of this period will become 4% in the second half of the next decade. Glass products account for 9% of annual sales. Glass bottles are being challenged by plastic products, but the most excellent glass is soy protein. Its barrier property and better sensory properties can often make up for its fragile defects

the development trend of packaging is having a complex impact on the glass industry, because glass is regarded as a packaging material with better quality than plastic. For drug manufacturers, image is becoming a higher priority. On the contrary, this trend is changing containers to blister eye packaging. Although the speed is slow, it is likely to increase the pace. In Britain, the traditional practice of pharmacists repacking tablets into bottles will be banned. As mentioned earlier, bottles used to repackage tablets are now often plastic

due to the impact of packaging regulations on glass sales, the consumption will decrease in the short term, and will further decline slightly in 2007. However, stable products will still use glass packaging, not only because of its good quality, but also because there is no choice in reality for some drug packaging

there is a trend to resist the use of glass bottles in the market. Even when the glass seems to be unchallengeable (such as the packaging of cough potion), some pharmaceutical companies are beginning to accept the shorter expiry date of products and have obtained the benefits of plastic packaging. Glass tubes can be used to produce ampoules, vials and syringes. In fact, only 5% of these products are made of non glass materials. This has become the main market of the glass industry, and accounts for the majority in quantity and value. With the development of many recombinant DNA products that can only be administered by non oral route, the production of ampoules and vials began to grow. However, with the development of needle free powder and liquid injection systems, the use of ordinary syringes will decline

there will be no progress in the type and use of glass, but competitive drug delivery methods can reduce the progress in the number and type of injections, especially in Europe, including nasal sprays, inhalants, oral forms (usually enteric coating), transdermal patches and needle free injection delivery systems, which will affect the sales of glass packaging


Copyright © 2011 JIN SHI